Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ADCT NASDAQ:CGC NASDAQ:FULC NASDAQ:IMUX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADCTADC Therapeutics$3.08-5.4%$2.98$1.05▼$3.97$345.37M2693,830 shs261,995 shsCGCCanopy Growth$1.80-4.3%$1.25$0.77▼$5.80$431.73M0.7630.23 million shs40.22 million shsFULCFulcrum Therapeutics$6.48-2.6%$7.10$2.32▼$9.30$350.51M2.82482,867 shs181,855 shsIMUXImmunic$0.82-5.7%$0.87$0.56▼$2.11$80.89M1.441.13 million shs1.37 million shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADCTADC Therapeutics0.00%-2.84%+10.81%-0.81%+4.95%CGCCanopy Growth0.00%+41.73%+74.76%+36.88%-65.97%FULCFulcrum Therapeutics0.00%-5.81%-3.71%-5.54%-26.94%IMUXImmunic0.00%-13.68%-12.78%+24.41%-41.84%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADCTADC Therapeutics1.2937 of 5 stars3.51.00.00.00.60.80.6CGCCanopy Growth0.5999 of 5 stars0.02.00.00.03.20.81.3FULCFulcrum Therapeutics0.9268 of 5 stars2.31.00.00.02.91.70.0IMUXImmunic2.6021 of 5 stars3.61.00.00.03.12.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADCTADC Therapeutics 3.00Buy$7.75152.03% UpsideCGCCanopy Growth 1.33SellN/AN/AFULCFulcrum Therapeutics 2.63Moderate Buy$7.5716.84% UpsideIMUXImmunic 3.29Buy$7.50814.63% UpsideCurrent Analyst Ratings BreakdownLatest IMUX, ADCT, FULC, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.008/12/2025CGCCanopy GrowthZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold8/8/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.006/25/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.006/20/2025ADCTADC TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeOutperform ➝ Moderate Buy$8.00 ➝ $5.006/13/2025ADCTADC TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.00 ➝ $10.006/5/2025IMUXImmunicD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00(Data available from 8/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADCTADC Therapeutics$70.84M4.88N/AN/A($2.10) per share-1.46CGCCanopy Growth$225.65M1.91N/AN/A$1.90 per share0.95FULCFulcrum Therapeutics$80M4.38N/AN/A$4.51 per share1.44IMUXImmunicN/AN/AN/AN/A$0.20 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADCTADC Therapeutics-$157.85M-$1.57N/AN/AN/A-220.00%N/A-53.73%11/6/2025 (Estimated)CGCCanopy Growth-$429.86M-$3.03N/AN/AN/A-155.76%-89.93%-44.24%11/14/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)IMUXImmunic-$100.51M-$1.23N/AN/AN/AN/A-461.46%-217.16%11/6/2025 (Estimated)Latest IMUX, ADCT, FULC, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025ADCTADC Therapeutics-$0.36-$0.50-$0.14-$0.50$17.82 million$18.84 million8/8/2025Q1 2026CGCCanopy Growth-$0.15-$0.14+$0.01-$0.16$64.98 million$52.98 million8/7/2025Q2 2025IMUXImmunic-$0.18-$0.20-$0.02-$0.20N/AN/A7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADCTADC TherapeuticsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AIMUXImmunicN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADCTADC TherapeuticsN/A4.934.66CGCCanopy Growth0.593.072.12FULCFulcrum TherapeuticsN/A24.4224.42IMUXImmunicN/A2.192.19Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADCTADC Therapeutics41.10%CGCCanopy Growth3.33%FULCFulcrum Therapeutics89.83%IMUXImmunic51.82%Insider OwnershipCompanyInsider OwnershipADCTADC Therapeutics5.40%CGCCanopy Growth0.16%FULCFulcrum Therapeutics7.00%IMUXImmunic4.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADCTADC Therapeutics310112.50 million106.42 millionOptionableCGCCanopy Growth3,150239.85 million239.47 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableIMUXImmunic7098.65 million94.11 millionOptionableIMUX, ADCT, FULC, and CGC HeadlinesRecent News About These CompaniesImmunic, Inc. (NASDAQ:IMUX) Receives Average Rating of "Buy" from BrokeragesAugust 27, 2025 | marketbeat.com1,059,484 Shares in Immunic, Inc. $IMUX Acquired by Aberdeen Group plcAugust 24, 2025 | marketbeat.comHC Wainwright Analysts Reduce Earnings Estimates for ImmunicAugust 16, 2025 | marketbeat.comWhat is Leerink Partnrs' Estimate for Immunic Q1 Earnings?August 12, 2025 | marketbeat.comWilliam Blair Predicts Immunic's Q1 Earnings (NASDAQ:IMUX)August 12, 2025 | marketbeat.comImmunic (NASDAQ:IMUX) Announces Quarterly Earnings ResultsAugust 11, 2025 | marketbeat.comImmunic, Inc. (IMUX) latest stock news and headlines – Yahoo FinanceAugust 10, 2025 | sg.finance.yahoo.comD. Boral Capital Reiterates Buy Rating for Immunic (NASDAQ:IMUX)August 9, 2025 | marketbeat.comImmunic reports promising Phase 2 data for lead drug candidate in progressive MS - ICYMIAugust 9, 2025 | proactiveinvestors.comImmunic (IMUX) Q2 Loss Widens 25%August 8, 2025 | theglobeandmail.comImmunic advances MS drug program with Phase 3 trials fully enrolledAugust 7, 2025 | proactiveinvestors.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ...August 7, 2025 | gurufocus.comImmunic, Inc. Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 7, 2025 | prnewswire.comImmunic (IMUX) to Release Quarterly Earnings on ThursdayAugust 7, 2025 | marketbeat.comImmunic, Inc. (NASDAQ:IMUX) Receives Consensus Recommendation of "Buy" from AnalystsJuly 31, 2025 | marketbeat.comImmunic Reports Positive Long-Term Safety, Tolerability Data for Vidofludimus Calcium in MS TrialJuly 25, 2025 | msn.comImmunic board authorizes up to 35 million stock ... - Investing.comJuly 13, 2025 | investing.comImmunic, Inc. (IMUX) Latest Stock News & Headlines - Yahoo FinanceJuly 9, 2025 | ca.finance.yahoo.comImmunic CEO discusses Phase 2 multiple sclerosis study success - ICYMIJune 28, 2025 | proactiveinvestors.comImmunic reveals long-term data supporting potential of MS drug vidofludimus calciumJune 24, 2025 | proactiveinvestors.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMUX, ADCT, FULC, and CGC Company DescriptionsADC Therapeutics NYSE:ADCT$3.08 -0.18 (-5.38%) Closing price 08/29/2025 03:59 PM EasternExtended Trading$3.16 +0.09 (+2.76%) As of 08/29/2025 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.Canopy Growth NASDAQ:CGC$1.80 -0.08 (-4.26%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$1.58 -0.22 (-12.44%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Fulcrum Therapeutics NASDAQ:FULC$6.48 -0.17 (-2.56%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$6.59 +0.11 (+1.70%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Immunic NASDAQ:IMUX$0.82 -0.05 (-5.75%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$0.82 +0.00 (+0.37%) As of 08/29/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 08/25 - 08/29 Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Tencent Music Stock Outshines Spotify as China’s Music Giant Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
